Completion↦Management↦Study Closure↦Notification of Closure
What is it? Why is it important?
The Ethics Committee (EC) or Regulatory Authorities (RA) such as Swissmedic (i.e. risk-category B and C studies) must be notified of study completion, discontinuation (early termination), or interruption.
A study is:
- Completed once the last study participant has completed his/her last planned visit (i.e. includes potential follow-up visits)
- Discontinued when stopped sooner than originally planned. Reasons include:
- Unexpected safety issues with a negative shift of the study`s risk-benefit ratio
- The efficacy of the investigational product (IMP/IMD) is better or worse than expected
- Temporarily Interrupted due to safety issues or concerns (i.e. regarding the risk-benefit ration of the study). The study can continue once safety issues are resolved
What do I need to do?
As a SP-INV, notify EC and if applicable Regulatory Authorities (RA) (e.g. Swissmedic, international) regarding study completion, discontinuation, or interruption.
For Investigational Medicinal Product (ClinO) studies notify:
- The EC (over BASEC) of study:
- Completion within Switzerland within 30 days
- Global completion within 90 days
- Discontinuation or interruption within 15 days
- Swissmedic (i.e. risk-category B and C) according to EC timelines
For Investigational Medical Device studies (ClinO-MD) notify:
- EC (over BASEC) of study:
- Completion, discontinuation, or interruption within 15 days.
- Discontinuation or interruption due to safety concerns within 24 hours
- Swissmedic (i.e. risk-category C) according to EC timelines
As a project leader of an HRO research project notify:
- The EC of study completion or discontinuation within 90 days
When discontinuing or interrupting a study describe:
- Reasons
- Consequences to study evaluation and results
- How many participants remain in the study (i.e. in Switzerland)
More
Notification to Swiss authorities is only applicable to studies implemented in Switzerland.
File any confirmation received by EC/RA in the trial master file (TMF) and the investigator site file (ISF) of the study. Also, in the event of multi-centre studies inform participating study sites of study closure (e.g. Site-INVs).
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissethics – see in particular
- Notification template of the completion or discontinuation of a clinical study or research project
- BASEC: EC submission portal
Swiss Law
ClinO – see in particular article
- Art. 38 Notification upon completion, discontinuation, or interruption of a study
ClinO-MD – see in particular articles
- Art. 36 Reporting the end, early termination and interruption of a clinical trial
- Art. 38 Notification and reporting to Swissmedic
HRO – see in particular article
- Art. 22, 36, 40, 43 Specifications regarding notification upon completion or discontinuation of a research project